Company intelligence / Profile preview
Vybion
California, United Statesvybion.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vybion’s lead candidate, INT41, is an AAV-delivered single-chain variable fragment (scFv) intrabody targeting the toxic N-terminal fragment of mutant huntingtin protein. In animal models of Huntington’s disease, INT41 reduced toxic protein accumulation and gene dysregulation and stabilized or improved motor and cognitive function. The company has received FDA Orphan Drug Designation for this program but has not yet entered clinical trials as of the latest available information.
- Therapeutic areas
- Neurology
- Modalities
- Intrabodies (scFv fragments)Gene therapy (AAV vectorized delivery)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CHDI Foundation (strategic agreement for animal studies leading to IND-enabling work)Past collaboration with Caltech on ProCode technology development
Beyond the preview
Go deeper on Vybion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vybion.